NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oncotelic Therapeutics' Deciparticle™ Platform and Its Impact on Drug Delivery
TL;DR
Oncotelic Therapeutics' nanotechnology platform offers a competitive edge by enabling effective intravenous delivery of previously difficult-to-administer cancer drugs, potentially improving treatment outcomes.
The Deciparticle platform uses nanotechnology to create uniform nanoparticles under 20nm, packaging water-resistant drugs and complex peptides for stable intravenous delivery across multiple therapeutic categories.
This technology could make cancer treatments more accessible and effective, potentially saving lives and reducing suffering for patients with difficult-to-treat cancers.
Oncotelic's platform can package even water-resistant drugs into tiny nanoparticles, including complex peptides like exenatide, revolutionizing how we deliver cancer treatments.
Found this article helpful?
Share it with your network and spread the knowledge!
The content focuses on Oncotelic Therapeutics Inc.'s Deciparticle™ platform, a scalable nanotechnology that transforms drug delivery by packaging water-resistant drugs and complex peptides into small, uniform nanoparticles for intravenous use in immunology and oncology treatments.
It expands treatment possibilities by enabling effective and safe intravenous delivery of previously difficult-to-administer drugs, including water-resistant compounds and complex peptides, which could improve outcomes in immunology and oncology.
The platform packages tough, water-resistant drugs and complex peptides into smaller, uniform nanoparticles that are small enough for effective and safe intravenous use, forming stable, monodisperse particles with diameters as small as less than 20 nm.
It has packaged all five main macrolide mTOR inhibitors (temsirolimus, sirolimus, ridaforolimus, Everolimus/Afinitor®, and umirolimus), tacrolimus, and complex peptides such as exenatide and cyclosporine A, demonstrating compatibility with both linear and cyclic peptides.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, led by CEO Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents.
New data was presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), highlighting the platform's capabilities in drug packaging and delivery.
The technology could transform paradigms in oncology treatments by enabling more effective delivery of a wider range of drugs, potentially addressing high-unmet-need cancers and rare pediatric indications with innovative therapeutic candidates.
Beyond its internal drug pipeline, Oncotelic licenses and codevelops select drug candidates through joint ventures, including owning 45% of GMP Bio, a joint venture advancing complementary drug candidates in oncology and rare disease therapeutics.
The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC, and the full article about the Deciparticle™ platform can be viewed at https://ibn.fm/Vq9CP.
Curated from InvestorBrandNetwork (IBN)
